Citi raised the firm’s price target on Nektar (NKTR) to $151 from $123 and keeps a Buy rating on the shares. The firm cites the positive alopecia areata data for the target boost. The firm now believes rezpeg could be utilized in the frontline setting ahead of JAK inhibitors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR: